Small cell lung cancer: from molecular biology to novel therapeutics (Q35608984)

9 August 2017

1 reference

title

Small cell lung cancer: from molecular biology to novel therapeutics (English)

1 reference

9 August 2017

0 references

3

Ravi Salgia

1 reference

9 August 2017

Evan Pisick

1

1 reference

9 August 2017

Simha Jagadeesh

series ordinal

2

1 reference

9 August 2017

publication date

1 November 2003

1 reference

Journal of Experimental Therapeutics & Oncology

9 August 2017

published in

1 reference

9 August 2017

volume

3

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

305-318

1 reference

Lung cancer mortality among males of Catalonia and Spain compared with other European countries between 1975-1977 and 1987-1989.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

A nonrandom chromosomal abnormality, del 3p(14–23), in human small cell lung cancer (SCLC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Chromosomal imbalances in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

The FHIT gene 3p14.2 is abnormal in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Organization of the gene encoding transcriptional repressor deltaEF1 and cross-species conservation of its domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

The role of p53-target genes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Clinical implications of the p53 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

21 January 2018

Regulators of cell death

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

The biology of stem cell factor and its receptor C-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Early signaling pathways activated by c-Kit in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Specific growth inhibition of small-cell lung cancer cells by adenovirus vector expressing antisense c-kit transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

HGF: a multifunctional growth factor controlling cell scattering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

21 January 2018

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

The role of phosphoinositide 3-kinase lipid products in cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Ten years of protein kinase B signalling: a hard Akt to follow

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including the ANA gene in human lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Mutation analysis of the PTEN/MMAC1 gene in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

The potential of protein kinase C as a target for anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Integrins: versatility, modulation, and signaling in cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Role of redox potential and reactive oxygen species in stress signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Redox regulation of cellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Role of oxidants/antioxidants in smoking-induced lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Angiogenesis and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Tumor staging and classification in lung cancer. Summary of the international symposium. Madrid, Spain, 3-4 December 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Surgery in the management of small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Superoxide dismutase as a target for the selective killing of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Expression of bcl-2--protein in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Pathology of small cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Prophylactic cranial irradiation in small cell lung cancer--an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

Matrix metalloproteinase inhibitors: a novel class of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1533-869X.2003.01103.X

10.1111/J.1533-869X.2003.01103.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference